Translate   8 w

https://www.selleckchem.com/pr....oducts/ademetionine.
Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the second-line treatment of patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. Lorlatinib is metabolized by cytochrome P450 (CYP) 3A and contraindicated with strong CYP3A inducers because of significant transaminase elevation. This phase I, open-label, two-period study evaluated the impact of a moderate CYP3A inducer, modafinil, on the safety and pharmacokinetics of lorlatinib. Healthy participants received single-dose oral

  • Like
  • Love
  • HaHa
  • WoW
  • Sad
  • Angry